155 related articles for article (PubMed ID: 11304776)
1. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Papadimitriou C; Dafni U; Bafaloukos D; Skarlos D; Moulopoulos LA; Razis E; Kalofonos HP; Aravantinos G; Briassoulis E; Papakostas P; Abela K; Gogas E; Kosmidis P; Pavlidis N; Dimopoulos MA
J Clin Oncol; 2001 Apr; 19(8):2232-9. PubMed ID: 11304776
[TBL] [Abstract][Full Text] [Related]
2. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Lalisang RI; Erdkamp FL; Rodenburg CJ; Knibbeler-van Rossum CT; Nortier JW; van Bochove A; Slee PH; Voest EE; Wils JA; Wals J; Loosveld OJ; Smals AE; Blijham GH; Tjan-Heijnen VC; Schouten HC
Breast Cancer Res Treat; 2011 Jul; 128(2):437-45. PubMed ID: 21584666
[TBL] [Abstract][Full Text] [Related]
5. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
6. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Fountzilas G; Dafni U; Gogas H; Linardou H; Kalofonos HP; Briasoulis E; Pectasides D; Samantas E; Bafaloukos D; Stathopoulos GP; Karina M; Papadimitriou C; Skarlos D; Pisanidis N; Papakostas P; Markopoulos C; Tzorakoeleftherakis E; Dimitrakakis K; Makrantonakis P; Xiros N; Polichronis A; Varthalitis I; Karanikiotis C; Dimopoulos AM;
Ann Oncol; 2008 May; 19(5):853-60. PubMed ID: 18042835
[TBL] [Abstract][Full Text] [Related]
7. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Skarlos D; Dafni U; Gogas H; Briasoulis E; Pectasides D; Papadimitriou C; Markopoulos C; Polychronis A; Kalofonos HP; Siafaka V; Kosmidis P; Timotheadou E; Tsavdaridis D; Bafaloukos D; Papakostas P; Razis E; Makrantonakis P; Aravantinos G; Christodoulou C; Dimopoulos AM
Ann Oncol; 2005 Nov; 16(11):1762-71. PubMed ID: 16148021
[TBL] [Abstract][Full Text] [Related]
8. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Razis E; Dimopoulos AM; Bafaloukos D; Papadimitriou C; Kalogera-Fountzila A; Kalofonos H; Briassoulis E; Samantas E; Keramopoulos A; Pavlidis N; Kosmidis P; Fountzilas G
Cancer Invest; 2001; 19(2):137-44. PubMed ID: 11296618
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
10. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
[TBL] [Abstract][Full Text] [Related]
13. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
[TBL] [Abstract][Full Text] [Related]
14. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
[TBL] [Abstract][Full Text] [Related]
15. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Kalofonos HP; Dafni U; Papadimitriou C; Bafaloukos D; Papakostas P; Kalogera-Fountzila A; Gogas H; Aravantinos G; Moulopoulos LA; Economopoulos T; Pectasides D; Maniadakis N; Siafaka V; Briasoulis E; Christodoulou C; Tsavdaridis D; Makrantonakis P; Razis E; Kosmidis P; Skarlos D; Dimopoulos MA
Ann Oncol; 2004 Oct; 15(10):1517-26. PubMed ID: 15367413
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
18. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Samantas E; Pectasides D; Pavlidis N; Kalofonos C; Klouvas G; Panoussaki E; Tsiakopoulos E; Poulakis N; Fountzilas G
Am J Clin Oncol; 1999 Feb; 22(1):87-93. PubMed ID: 10025390
[TBL] [Abstract][Full Text] [Related]
19. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Botti G; Di Bonito M; De Rosa V; Iodice G; Rubulotta MR; Comella G;
Br J Cancer; 2006 Oct; 95(8):1005-12. PubMed ID: 17047649
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Ries F; Duhem C; Kleiber K; Dicato M
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
